Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;74(9):1041-5.
doi: 10.1007/s40265-014-0241-5.

Delamanid: first global approval

Nicola J Ryan  1 , Jin Han Lo
Affiliations
Review

Delamanid: first global approval

Nicola J Ryan et al. Drugs. 2014 Jun.

Abstract

Delamanid, a nitro-dihydro-imidazooxazole derivative, has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimised background therapy. It is also under review for marketing in Japan for MDR-TB, the first drug application filed in Japan for this indication. Delamanid has been granted orphan drug status in both the EU and Japan. This article summarizes the milestones in the development of delamanid leading to this first approval for MDR-TB.

PubMed Disclaimer

References

    1. Eur Respir J. 2013 Jun;41(6):1393-400 - PubMed
    1. Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54 - PubMed
    1. Ther Adv Respir Dis. 2012 Oct;6(5):255-68 - PubMed
    1. Eur J Med Chem. 2012 May;51:1-16 - PubMed
    1. Antimicrob Agents Chemother. 2009 Mar;53(3):849-62 - PubMed

MeSH terms

LinkOut - more resources